Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy.

Journal for immunotherapy of cancer·2026
Same author

Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.

Breast cancer research : BCR·2026
Same author

B7-H4 in cancer immune evasion and immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

PALINCODE: Recording cell lineage with ternary palindromic CRISPR bits.

bioRxiv : the preprint server for biology·2026
Same author

Fatty acids in the tumor microenvironment reprogram neutrophils to induce immunosuppression via adenosine.

bioRxiv : the preprint server for biology·2026
Same author

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

Nature communications·2026
Same journal

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026
Same journal

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.

Targeted oncology·2026
Same journal

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.

Targeted oncology·2026
Same journal

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

Targeted oncology·2026
Same journal

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Targeted oncology·2026
Same journal

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Targeted oncology·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Targeting regulatory T cells.

Christine Ménétrier-Caux1, Tyler Curiel, Julien Faget

  • 1Université de Lyon, F-69000, Lyon, France. christine.caux@lyon.unicancer.fr

Targeted Oncology
|February 14, 2012
PubMed
Summary
This summary is machine-generated.

T regulatory cells (Treg) create an immunosuppressive tumor environment, hindering anti-cancer immunity. Inhibiting Treg function shows promise for improving cancer immunotherapy efficacy in both animal models and human treatments.

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Related Experiment Videos

Last Updated: May 25, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Cancers express tumor antigens, yet spontaneous immune rejection is rare, indicating a need to understand immune evasion mechanisms.
  • CD4(+)CD25(high) T regulatory cells (Treg) are key mediators of immune suppression in established cancers.
  • The tumor microenvironment often fosters an immunosuppressive milieu, limiting effective host antitumor responses.

Purpose of the Study:

  • To review Treg subpopulations and their suppressive mechanisms in cancer.
  • To explore the potential of Treg inhibition for enhancing antitumor immunity.
  • To discuss strategies for developing Treg-targeting cancer immunotherapies.

Main Methods:

  • Literature review of Treg biology and function in cancer.
  • Analysis of studies involving Treg depletion in preclinical cancer models.
  • Examination of current and proposed immunotherapeutic strategies targeting Tregs.

Main Results:

  • Treg depletion enhances endogenous antitumor immunity in animal cancer models.
  • Inhibition of Treg function improves the efficacy of active immunotherapy in preclinical settings.
  • Evidence suggests Treg targeting could overcome limitations in human cancer immunotherapy.

Conclusions:

  • Tregs are critical suppressors of antitumor immunity in cancer.
  • Targeting Treg function represents a promising strategy to enhance cancer immunotherapy.
  • Further research into Treg-specific immunotherapies is warranted for clinical application.